Live Breaking News & Updates on Cholangiocarcinoma

Stay updated with breaking news from Cholangiocarcinoma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Can I Make an Impact This Cholangiocarcinoma Awareness Month?

I wondered how much I could contribute to cholangiocarcinoma awareness, but determined that if I help just one person, then that's a success. ....

Cholangiocarcinoma Awareness , Share Your Story ,

Monitoring and Managing Hyperphosphatemia

Hyperphosphatemia is the most common AE associated with FGFRi treatments and can impact patient quality of life, but there are treatments and possible diet changes that may help mitigate this AE. ....

Chaundra Bishop , R Katie Kelley , Caroline Kuhlman , Lipika Goyal , Taiho Oncology Inc , Taiho Oncology , Onclive Insights , Bile Duct Cancer , Biliary Tract Cancer , Intrahepatic Cholangiocarcinoma , Extrahepatic Cholangiocarcinoma , Adverse Events , Fgfr Inhibitors , Fgfr Inhibitors Adverse Effects , Patient Monitoring ,

TYRA-300 designated rare pediatric disease drug; Tyra collects $200M

A rare pediatric disease designation for its achondroplasia treatment and a subsequent $200 million private placement boosted shares of Tyra Biosciences Inc. on Feb. 2 by 29.3%. ....

Tyra Biosciences Inc , Tyra Biosciences , Rare Pediatric Disease Designation , Tyra 300 , Tyra Biosciences Inc , Tyra 200 , Priority Review Voucher ,

FDA Grants Fast Track Designation to BST02 for Liver Cancer

The FDA has granted a fast track designation to the T-cell therapy BST02 for the treatment of patients with all forms of liver cancer. ....

China National Drug Administration , Common Adverse Event Evaluation , Fast Track Designation , Liver Cancer , Hepatocellular Carcinoma ,

Patient Perspective Regarding FGFRi Adverse Event Profiles

A patient with cholangiocarcinoma shares her experience while being treated with an FGFR inhibitor, as well as insights on what providers should tell their patients to help them best manage or possibly prevent these adverse events. ....

Chaundra Bishop , Caroline Kuhlman , Lipika Goyal , R Katie Kelley , Onclive Insights , Bile Duct Cancer , Intrahepatic Cholangiocarcinoma , Extrahepatic Cholangiocarcinoma , Fgfr Inhibitors , Fgfri Adverse Events , Adverse Events , Fgfr Inhibitors Adverse Effects , Fgfr Inhibitors Side Effects , Biliary Tract Cancer ,